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ABSTRACT
In an era where mutational profiles inform treatment options, it is critical to 
know the extent to which tumor biopsies represent the molecular profile of the 
primary and metastatic tumor. Head and neck squamous cell carcinoma (HNSCC) 
arise primarily in the mucosal lining of oral cavity and oropharynx. Despite aggressive 
therapy the 5-year survival rate is at 50%. The primary objective of this study is to 
characterize the degree of intratumor mutational heterogeneity in HNSCC. We used 
multi-region sequencing of paired primary and metastatic tumor DNA of 24 spatially 
distinct samples from seven patients with HNSCC of larynx, floor of the mouth (FOM) 
or oral tongue. Full length, in-depth sequencing of 202 genes implicated in cancer 
was carried out. Larynx and FOM tumors had more than 69.2% unique SNVs between 
the paired primary and metastatic lesions. In contrast, the oral tongue HNSCC had 
only 33.3% unique SNVs across multiple sites. In addition, HNSCC of the oral tongue 
had fewer mutations than larynx and FOM tumors. These findings were validated on 
the Affymetrix whole genome 6.0 array platform and were consistent with data from 
The Cancer Genome Atlas (TCGA). This is the first report demonstrating differences 
in mutational heterogeneity varying by subsite in HNSCC. The heterogeneity 
within laryngeal tumor specimens may lead to an underestimation of the genetic 
abnormalities within tumors and may foster resistance to standard treatment 
protocols. These findings are relevant to investigators and clinicians developing 
personalized cancer treatments based on identification of specific mutations in tumor 
biopsies.
Oncotarget27186www.impactjournals.com/oncotarget
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common cancer in the world, with nearly 
600,000 new cases diagnosed annually [1]. Despite a vast 
array of research on HNSCC and development of new 
and less toxic treatment regimens, the survival rates of 
HNSCC have not dramatically changed over the last 50 
years, with overall survival of approximately 50% [2]. 
This somewhat guarded outcome is, in part due to the 
development of chemotherapy and radiation resistance 
following an initial response, leading to locoregional and 
distant failures. A major factor contributing to this is the 
presence of intratumor genetic heterogeneity [3].
Great strides have been made in understanding the 
“mutational landscape” of head and neck squamous cell 
carcinoma (HNSCC) [4, 5]. With increasing incidence of 
HNSCC in younger patients, a recent report demonstrates 
that mutational frequencies in oral tongue tumors from 
young patients are similar to older patients [6]. The 
majority of HNSCC genomic studies have analyzed 
single samples from individual tumors, which does not 
allow for an understanding of intratumor heterogeneity. 
While the development of cancer is presumed to be due 
to clonal expansion of tumor cells [7], studies suggest 
that continued acquisition of mutations in the clones, 
leads to a heterogeneous population of cells within 
the tumor resulting in the development of selective 
resistances to therapies through Darwinian selection [8-
11]. Understanding the genetic heterogeneity of tumors, 
as well as the evolution of further genetic alterations is of 
critical importance to the development of therapies aimed 
at eradicating all clones to successfully treat HNSCC. 
Two recent studies have also utilized next-generation 
sequencing technologies to demonstrate a high level of 
intratumor heterogeneity in HNSCC [3, 9]. Widespread 
intratumor heterogeneity was reported in specimens from 
different regions of the primary tumor and corresponding 
metastatic lymph nodes from a single patient with HNSCC 
[3]. Further, they reconstructed an evolution of these 
changes throughout the tumor clones evaluated, showing 
that the development of genetic alterations that were 
present in metastatic samples arose as late events. Mroz 
et. al., also demonstrated that a higher level of genetic 
heterogeneity portended a worse prognosis in HNSCC 
[9]. Overall, intratumor heterogeneity appears to be 
an important factor in both treatment and prognosis for 
HNSCC. 
This concept of intratumor heterogeneity is also 
an important consideration as we move toward the era 
of personalized medicine [12]. Therapies that have been 
developed targeting specific antigens or markers on 
tumor cells rely on the ubiquity of expression of these 
markers on the tumor cell to have therapeutic value [13, 
14]. Recently, the p.E322K mutation in MAPK1 was 
reported to confer exquisite sensitivity to small molecule 
inhibitor erlotinib in a patient with tongue cancer [15]. 
The presence or absence of such markers is usually 
determined by single biopsies taken from tumors with 
the implicit assumption that expression of markers in the 
biopsy specimen is representative of the tumor as a whole. 
Recently, Gerlinger et al. demonstrated an intratuomor 
heterogeneity from single-biopsy sample of metastatic 
renal-cell carcinoma suggest that the distinct mutations 
in mTOR, SETD2, PTEN, and KDM5C genes can cause 
convergent phenotypic evolution of tumor [8]. However, it 
is a great challenge but understanding genomics landscape 
depicted from single tumor-biopsy samples may expose to 
the development of effective personalized-medicine and 
biomarker.
In this manuscript, we aimed to determine the 
degree of intratumor heterogeneity within both primary 
tumors and in metastatic lymph nodes among seven 
patients with oral tongue, FOM or laryngeal HPV negative 
HNSCC. We carried out deep sequencing of 202 genes 
implicated in cancer and validated the findings using the 
Affymetrix array platform and The Cancer Genome Atlas 
(TCGA) HNSCC dataset. Comparing oral tongue, FOM 
and laryngeal cancer specimens, we were able to show 
a greater level of intratumor genetic heterogeneity in the 
laryngeal tumors. 
RESULTS
Patient characteristics
The patients ranged in age from 40 to 63 years, 
with a median of 57 years, five patients were male and 
two female (patient 4 and 7 with oral tongue and larynx 
tumors, respectively). All patients in the group were 
Caucasian (Supplemental Table 1). Six of seven patients 
had a history of smoking at the time of diagnosis, with 
only one patient having never smoked (patient 4 with a 
tongue tumor). Five of the seven patients had a history of 
alcohol consumption and all were still actively drinking at 
the time of diagnosis. Four of the seven patients (57.1%) 
had a primary tumor located in the oral tongue, one patient 
(14.3%) had an anterior floor-of-mouth primary tumor 
and two patients (28.6%) had supraglottic laryngeal 
primary squamous cell carcinoma. All patients were 
treatment naïve with the exception of patient 2. Patient 
2 with a recurrent oral tongue tumor was previously 
treated with cisplatin and radiation therapy. Patient 7 
had a new primary in the larynx. The first laryngeal SCC 
that occurred 10 y prior was an indolent T1N0 involving 
a different site of the larynx. The patient had no prior 
chemotherapy or radiation treatment. We tested the tumor 
samples for HPV positivity using immunohistochemistry, 
in situ hybridization and quantitative PCR. All samples 
were clinically negative for HPV infection. No evidence 
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of HPV was identified with a sensitive real time qPCR 
assay capable of identifying the presence of 15 different 
serotypes of HPV (Supplemental Table 2). 
Degree of SNV heterogeneity varies by sub-site
Specimens were collected from 2-3 locations 
separated by at least 5 mm in the primary tumor (P) 
and in most cases, the matched metastatic lymph node 
(M) to evaluate the degree of intratumoral mutational 
heterogeneity (Figure 1A). Tumor content was assessed 
using H&E staining of specimens to confirm > 70% tumor 
by volume of specimen. Of 202 genes (MTOR, NRAS, 
NOTCH2, FLG, IL6R, SPTA1, SPEN, DDR2, PAPPA2, 
HMCN1, USH2A, RYR2, ZNF238, ARID1A, CSMD2, 
MPL, JAK1, ERCC3, LRP1B, LRP2, ITGA4, CASP8, 
IDH1, PIKFYVE, IRS1, DNMT3A, ALK, SOS1, EML4, 
MSH2, MSH6, VHL, RAF1, FOXL2, ATR, MECOM, 
PIK3CA, ETV5, TGFBR2, MLH1, MYD88, CTNNB1, 
SETD2, PBRM1, BAP1, MITF, EPHA3, TET2, CRIPAK, 
FBXW7, FGFR3, WHSC1, PDGFRA, KIT, KDR, LPHN3, 
APC, CSF1R, PDGFRB, GABRA6, NPM1, FGFR4, NSD1, 
FLT4, CDH10, ADAMTS12, HEATR7B2, MAP3K1, 
PIK3R1, PRDM1, TNFAIP3, ESR1, SYNE1, MAP3K4, 
DDR1, NOTCH4, DAXX, PKHD1, BAI3, MDN1, RELN, 
PIK3CG, PPP1R3A, MET, SMO, BRAF, PRSS1, EZH2, 
MLL3, HDAC9, CARD11, IKZF1, EGFR, ELN, HGF, 
PCLO, CDK6, RIMS2, PKHD1L1, CSMD3, COL14A1, 
FAM135B, PTK2, CSMD1, FGFR1, KCNB2, RUNX1T1, 
PPP2R4, ABL1, TSC1, NOTCH1, CDKN2A, PAX5, JAK2, 
GNAQ, SYK, PTCH1, NFKB2, FGFR2, RET, PCDH15, 
GATA3, PTEN, CYP2C19, ATM, CBL, CHEK1, WT1, 
HRAS, MEN1, FAT3, PTPN11, HNF1A, KRAS, AKAP3, 
MLL2, ACVR1B, ERBB3, LRP1, CDK4, NAV3, ERCC5, 
FLT3, FLT1, BRCA2, RB1, TBC1D4, AKT1, SYNE2, 
TSHR, GABRB3, RAD51, MAP2K1, IDH2, IGF1R, 
ERCC4, TSC2, PALB2, CD19, CREBBP, CYLD, CDH11, 
CDH1, HYDIN, MAP2K4, NCOR1, NF1, HNF1B, ERBB2, 
TOP2A, BRCA1, SPOP, TP53, RNF213, AURKB, SMAD4, 
LAMA1, SMARCA4, STK11, NOTCH3, CPAMD8, JAK3, 
ZNF536, GNA11, CEBPA, TGFb1, PPP2R1A, ASXL1, 
TOP1, AURKA, GNAS, RUNX1, SMARCB1, CHEK2, 
NF2, EP300, KDM6A, ARAF, GATA1, FAM123B, AR 
and ATRX) analyzed, 57 genes had a total of 102 somatic 
single nucleotide variations in at least one of the primary 
or metastatic sites across the seven patients (Supplemental 
Table 3). None of the SNVs were shared between patients. 
Of the SNVs detected, 71 were only seen in primary 
tumor specimens with 48 being present in only one 
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sample from the primary tumor. Overall there was a much 
higher number of SNVs identified in laryngeal tumors 
(72 distinct SNVs) compared to oral tongue tumors (24 
distinct SNVs). 
When the degree of heterogeneity was evaluated 
based on sub-site, oral tongue tumors were found to 
have fewer mutations with only 33.3% of SNVs being 
distinct between specimens from the same patient 
compared to laryngeal tumors (Figure 1B). There was less 
heterogeneity between oral tongue tumors with 0/4, 0/4 
and 1/7 unique SNVs in the 200 gene panel in patients 4, 
5 and 6, respectively. Patient 2 with the previously treated 
recurrent oral tongue tumor demonstrated a total of 7/9 
unique SNVs. Laryngeal and FOM tumors (Figure 1C) 
demonstrated higher level of intratumor heterogeneity 
compared to oral tongue tumors, showing 69.2% of SNVs 
which were not shared among all specimens from the same 
patient (χ2 (df=1) =5.02, exact p = 0.029). 
The majority of SNVs conferred a missense 
mutation (82%) to the gene affected (Figure 1D). The 
number of missense mutations in laryngeal tumor 
specimens was not significantly different from oral tongue 
specimens (χ2 (df=1) = 0.7, exact p = 0.7). Patient 5 had 
somatic mutations in HRAS p.G13C, CASP8 p.R127* 
and PDGFRA p.R764H at all sub-sites in primary and 
metastatic tumor samples again consistent with these 
being truncal events. The substitutions in TP53 and HRAS 
have been previously reported in COSMIC consistent with 
these being driver mutations. The p.R127* substitution 
in CASP8 a protein critical in the initiation phase of 
apoptosis has not been reported; however, inactivating 
substitutions and frame-shift mutations in CASP8 have 
been reported [16, 17]. Finally, p.R764H substitution in 
PDGFRA has not been previously reported; however, this 
substitution is within the kinase domain of PDGFRA (a.a. 
593-948; PF07714). 
Two oral tongue tumors had somatic point mutations 
identified in TP53 p.R282W in patient 6 and p.S241F in 
patient 2 in primary sub-sites and metastatic sub-sites 
consistent with this being a truncal event. In patient 7 
(laryngeal tumor), a substitution at amino acid residue 
p.I251N in the TP53 gene was observed in two sub-sites 
(A and B separated by a distance of 1 cm) of the primary 
tumor (Figure 2). Interestingly, another TP53 mutation, 
p.Y236C separated by 45 bases from p.I251N, was unique 
to sub-site A. Further examination of each sequencing read 
from TP53 fragments spanning the amino acid residues 
p.I251N and p.Y236C were carried out. We observed 
21.86% alteration (T replaced by C) at amino acid residue 
p.Y236C and 6.87% alteration (A replaced by T) at 
p.I251N in the sub-site A. Further, at the tumor sub-site B, 
there was no alteration at p.Y236C and 59.23% alteration 
(A replaced by T) at p.I251N. Thus the p.I251N alteration 
at sub-site A developed independently of the p.Y236C 
alteration at tumor sub-site B. The number of nucleotide 
alterations in sub-site A and B laryngeal primary tumor 
from patient 7 were counted manually and the percentage 
calculated based on the Integrative Genomics Viewer 
(IGV) results. 
Figure 1: Degree of SNV heterogeneity varies based on sub-site. A. Schematic depicting specimen acquisition from the primary 
(P) tumor or metastatic (M) lymph node. HNSCC specimens were taken from multiple locations separated by a distance of at least 5 mm at 
the primary tumor site and in most cases, paired metastatic lymph node. Figure demonstrating SNVs present (blue/orange) or absent (white) 
within primary (P) or metastatic (M) B. oral tongue HNSCC (patient 2, 4, 5 and 6), and C. laryngeal (patient 1 and 7) and FOM (patient 3) 
HNSCC. D. Functional consequences of SNVs present within tumor specimens are depicted in the bar graph. The majority of mutations 
from various sites were missense mutations.
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Copy number variations depend on the sub-site 
of origin
Frequently an amplification in the number of copies 
of a particular gene results in increased expression of 
the gene product contributing to the disease process. A 
total of 175 of the 202 genes (86.6%) demonstrated copy 
number variations (CNV) (Supplemental Table 4). Of 
the 175 genes with CNVs identified, 114 of these were 
shared between multiple patients. Of these CNVs (whether 
amplification, deletion, or both) 52 were shared between 
two patients, 50 were shared between three patients, nine 
shared between four patients, and three shared between 
five patients. There were 202 and 110 genes with CNVs in 
laryngeal and FOM tumors respectively, (Figure 3A). In 
contrast, oral tongue tumors demonstrated CNVs in a total 
of 62 genes (Figure 3B). A total of 22 genes demonstrated 
loss of heterozygosity (LOH). Larynx tumors had a higher 
number of genes with LOH (14 genes) compared to oral 
tongue tumors (8 genes). 
Phylogenetic analysis of mutations
Phylogenetic trees were generated on clusters of 
mutations (e.g. Missense, Nonsense and Synonymous) 
to determine the clonal evolution of tumors relative to 
the germline non-mutated sequence (Figure 4A-4N). In 
addition, we listed the unique and commonly mutated 
gene names in an evolutionary model of these tumors. 
The length of the trunk and branches on phylogenic 
trees denote the number of mutations in that lineage. 
Mutated genes that are common between the primary 
and metastatic tumors are listed in the trunk below 
Figure 2: TP53 mutations p.I251N and p.Y236C within the primary laryngeal tumor sub-sites developed independent 
of each other. The primary tumor from patient 7 was assessed for mutations in TP53 at 2 sites separated by a distance of 1 cm. Two 
specific mutations in TP53 that were separated by 45 bases were analyzed in each sequencing read (gray bars). Across all sequencing reads, 
tumor A had 6.87% alterations in the amino acid residue p.I251N and 21.86% alterations in p.Y236C. Tumor B had 59.23% alterations in 
the p.I251N residue and no alteration in p.Y236C. Thus, mutations in p.I251N and p.Y236C residues emerged independently at different 
sites (A and B) within the primary tumor. 
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Figure 3: Heterogeneity in copy number varies based on the sub-site or origin. The copy number variability identified within 
A. laryngeal (patient 1 and 7) and FOM (patient 3) tumors, and B. oral tongue tumors. The key specifies the color code to depict the status 
of CNVs in each gene. Larynx and FOM tumors demonstrated significantly higher number of CNVs compared to oral tongue tumors.
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Figure 4: Evolutionary analyses of mutated codons in HNSCC from various sites. Panels A., C., E., G., I., K. and  M. 
represent midpoint-rooted phylogenetic trees of the tumors using the maximum likelihood approach. The branch lengths are proportional 
to the number of nonsynonymous mutations between the branching points. The scale bar represents 0.1 substitutions per site. Panels B., D., 
F., H., J., L. and N. represent the evolutionary models of tumors in each patient and list the mutated genes in each cluster. The commonly 
mutated genes are in dark blue and genes with unique mutations are listed below the brown and orange lines for the primary and metastatic 
tumor, respectively. 
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(blue). Unique mutations that evolve in the primary 
or metastatic tumor are listed in the branches colored 
brown and orange, respectively. For instance, in patient 
3, HMCN1 is commonly mutated in all specimens and 
hence listed next to the trunk. Unique mutations in PCLO 
and CSMD3 in P3A and P3B, respectively and FLG, 
MLL3 and SPEN in metastatic tumor M3A are listed in 
the branches. The metastatic tongue tumor from patient 
2 was phylogenetically closer to the normal than the 
primary tumor. This indicated that P2A, P2B and M2A 
evolved from a precursor primary tumor with mutations 
in TP53 and PIK3CA genes. Similarly, metastatic tumors 
in patient 1 were phylogenetically closer to the normal 
compared to the primary laryngeal tumor indicating that 
all these tumors originated from an unsampled tumor 
that subsequently acquired additional mutations detected 
in P1A and P1B. The laryngeal tumor from patient 7 
demonstrates a high degree of mutations in P7A and 
P7B specimens indicating a high level of intratumoral 
heterogeneity. 
Affymetrix and TCGA analysis validates deep 
sequencing data of HNSCC
Affymetrix whole genome SNP array data obtained 
from oral tongue (patient 5) and larynx (patient 1) tumors 
were analyzed using the Genotyping Console Software 
4.2. Analysis of the SNV, CNV, and LOH confirmed a 
significantly higher rate of alterations in the laryngeal 
tumors as compared to oral tongue tumors (χ2 (df=2) = 
231.7, exact p < 0.001) (Figure 5A). Further, analyses 
of The Cancer Genome Atlas (TCGA) data revealed that 
oral cavity tumors have significantly fewer mutations than 
laryngeal tumors (χ2 (df=1) = 23.45, exact p < 0.0001) 
(Figure 5B). 
DISCUSSION
While the development of cancer is presumed to be 
due to clonal expansion of tumor cells [7], studies suggest 
that during this expansion there is continued acquisition 
of mutations in the clones, leading to a heterogeneous 
population of cells within the tumor [8-11]. Recent work 
on renal cell carcinoma and pancreatic carcinoma have 
demonstrated significant intratumor heterogeneity, and 
suggest that metastatic potential of these tumors may 
develop late in their evolution and from only a small 
subset of the tumor cells [8, 18]. The maintenance of these 
heterogeneous populations within the tumor can lead to the 
development of selective resistance to therapies through 
Darwinian selection [8, 10]. Our evaluation of HNSCC 
specimens from seven patients shows that intratumor 
heterogeneity in HNSCC varies based on the sub-site in 
which the tumor arises. All tumors evaluated had varying 
degrees of mutational heterogeneity when evaluating both 
SNVs and CNVs between tumor specimens. This is the 
first report to demonstrate that intratumor heterogeneity in 
HNSCC varies by primary site of the tumor in question. 
Stransky et al. demonstrated in a well-designed 
study of 92 patients that a large number of genes are 
altered in HNSCC, with a large portion of these genes 
involved in squamous differentiation [4]. Many mutations 
in a wide array of genes related to epithelial differentiation 
Figure 5: Affymetrix SNP 6.0 array and TCGA data analysis demonstrate that oral cavity tumors have fewer mutations 
than larynx tumors. A. Number of single nucleotide variations (SNV), copy number variations (CNV) and loss of heterozygosity 
(LOH) in all samples from patient 1 (larynx tumor) and patient 5 (oral tongue tumor) are graphed. Numbers in the stacked bars indicate the 
number of mutations. B. TCGA analyses of percentage of genes with low (0-200) or high (200-400) number of mutations in tumor from 
oral cavity or larynx.
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were found, however they also noted that there seemed 
to be unifying features of HNSCC despite the sub-site 
of origin in the tumors they evaluated. As an example, 
TP53 in their study was found to be inactivated in nearly 
all patients evaluated. This study was not designed to 
evaluate intratumor heterogeneity, as samples used 
were from single biopsy specimens from each patient. 
TP53 mutations were similarly identified in the current 
study; however, these mutations were heterogeneously 
present within the specimens evaluated. While studies 
demonstrating the various mutations present throughout 
the genome of HNSCC cases are of importance, it remains 
crucial to take into account the presence of intratumor 
heterogeneity in treatment planning.
Mroz et al. utilized a process they developed 
deemed mutant-allele tumor heterogeneity (MATH) to 
evaluate heterogeneity in tumor specimens [9]. Through 
this technique, they determined that increased levels of 
heterogeneity within the tumors depending on HPV status 
conferred a poorer prognosis for HNSCC. Further, the 
authors demonstrated that the degree of heterogeneity was 
more strongly associated with poor prognosis than either 
HPV status of the tumor or the presence of a deleterious 
mutation in the TP53 gene. In a more recent application 
of MATH analyses to the TCGA cohort, Mroz et al 
reported that high MATH values indicative of increased 
heterogeneity correlated with reduced overall survival 
[19]. It would be interesting to correlate patient survival to 
the extent of mutations in the tumor. Our data demonstrate 
that direct evaluation of multiple specimens from HNSCC 
tumors reveals an underappreciated difference in the 
number of mutations based on site.
Various differences between the larynx, FOM 
and the oral tongue may account for the disparity of 
incidence in mutations at these sites. The anterior two-
thirds [20] of the tongue and the floor-of-mouth arise from 
embryological arches 1 and 2, while the larynx develops 
from arches 3 and 4. The oral cavity is made up of 
pseudostratified epithelium to be more resilient to trauma 
during mastication, while the larynx has respiratory 
epithelium and is primarily exposed to air. The FOM is 
a horseshoe-shaped region beneath the tongue. HNSCC 
in the FOM can demonstrate rapid progression that is 
difficult to control locally and regionally. The most likely 
cause for the differences in mutation rates between various 
sites could be the extent of carcinogen exposure at these 
sites. The oral tongue has a larger surface area compared 
to the larynx. Further, the larynx is exposed to carcinogens 
during both inhalation and exhalation. As air flows over 
the larynx, eddy currents created by the false vocal cords 
increases exposure to the region. The increased exposure 
to carcinogen could account for an increase in mutation 
rates in tumors of the larynx compared to the oral tongue. 
This study provides evidence that the degree of 
intratumor heterogeneity in squamous cell carcinoma 
varies by location of the primary tumor. These data 
demonstrate that, although multi region sampling is needed 
to fully assess intratumor heterogeneity, single-biopsy 
may adequately represent mutations in oral cavity tumors. 
Studies in much larger cohorts with comprehensive 
clinical annotation and repeat biopsy at relapse are needed 
to fully understand the clinical relevance of intratumor 
heterogeneity in head and neck cancer. Moreover, detail 
study of epigenetic and phenotypic evaluation through 
DNA methylation, chromatin remodeling, RNA and 
protein expression studies are needed to fully understand 
the impact of intratumor heterogeneity on tumor biology 
and response to therapy.
MATERIALS AND METHODS 
Sample collection and genomic DNA preparation
Research involving collection of tissues and clinical 
information from human subjects was approved by the 
Institutional Review Board of the University of Pittsburgh, 
and informed consent was obtained from each patient 
prior to tissue collection. Patients undergoing resection of 
HNSCC were considered for inclusion in this study. Seven 
patients with HNSCC were included in the study. In each 
case, specimens were collected from at least two separate 
locations of the primary tumor and in most cases from 
two separate locations of a metastatic lymph node. These 
samples were separated by at least 5 mm, with a range of 
5-37 mm between samples (Supplemental Table 5). Details 
of patient’s tumor tissues information are summarized in 
Supplemental Table 5. Blood samples were also collected 
from patients to evaluate the genomic DNA from 
lymphocytes as controls for germ line genetic alterations 
in each patient. Blood samples were centrifuged and the 
“buffy coat” was harvested for collection of lymphocytes. 
Tissue specimens were embedded in Tissue-Tek OCT 
compound (Sakura Finetek, Torrance, CA), sectioned at 
20 µm thickness (12 sections per sample) and collected in 
tubes for DNA extraction. One 8 µm section was collected 
before and after the 20 µm sections for histological 
analyses of hematoxyllin and eosin stained sections to 
ensure presence of > 70% tumor cells. DNA was extracted 
using the Qiagen DNA mini kit (Valencia, CA), following 
manufacturer’s instructions. DNA was quantified using 
PicoGreen dsDNA Quantitation Reagent (Invitrogen, 
Carlsbad, CA). 
HPV testing
HPV infection status in tissues was determined as 
previously described using FISH and multi-plex PCR [21, 
22]. For quantitative PCR analyses briefly, HPV testing 
was performed on OCT embedded tissue samples using 
the COMPLeTe Care HPV test (Physicians Reference 
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Laboratory, LLC, Overland Park, KS), a multiplex real-
time PCR test that simultaneously detects, types, and 
quantifies all 15 high-risk HPV types known to cause 
anogenital cancer. Five to 10 tissue sections (5 μm each) 
were used to extract DNA using a QIAmp tissue kit 
(Qiagen, Valencia, CA). Four multiplex reactions, each 
targeting four high-risk HPV types, were performed in a 
LightCycler 480 instrument using 8 μL of extracted DNA 
per multiplex reaction to detect all 15 high-risk HPV types 
and an internal control in which HPV 16 was detected 
in two multiplex reactions. Quantitative standards and 
controls for each of the high-risk types and internal control 
β-globin were included in each run. The high-risk HPV 
subtypes tested were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 68, 73, and 82, chosen according to a consensus 
from several epidemiologic studies. The COMPLeTe Care 
HPV test targets E7 of the HPV genome, an oncogene, 
the presence of which is required for oncogenesis. Unlike 
capsid gene L1, which is reported to be lost on integration 
of the HPV genome into the host chromosome, the 
oncogenes E6 and E7 are stable. The test also detects and 
quantifies the β-globin (HBB) gene as an internal control.
Genomic DNA library preparation
Genomic DNA was quantified by Qubit (Invitrogen, 
Carlsbad, CA) and quality was accessed using Genomic 
DNA Tape for the 2200 Tapestation (Agilent Technologies, 
Santa Clara, CA). DNA from each sample (200-500 ng 
of genomic DNA) was sheared by sonication with the 
following conditions: Peak Incident Power 175, Duty 
Cycle 20%, Intensity 5, Cycles per Burst 200, and 120 
seconds using Covaris E220 instrument (Covaris Inc., 
Woburn, MA). To ensure the proper fragment size, 
sonicated DNA samples were checked on TapeStation 
using the DNA High Sensitivity kit (Agilent Technologies, 
Santa Clara, CA). The sheared DNA proceeded to library 
prep using KAPA library prep kit (KAPA) following the 
“with beads” manufacturer protocol. Briefly, this protocol 
consists of 3 enzymatic reactions for end repair, A-tailing 
and BioO adaptor ligation, followed by barcode (BioO 
Scientific, Austin, Texas) insertion by PCR using KAPA 
HiFi polymerase (6 cycles). PCR primers were removed 
by using 1.8x volume of Agencourt AMPure PCR 
Purification kit (Beckman Coulter, Brea, CA). At the end 
of the library prep, samples were analyzed on TapeStation 
to verify correct fragment size and to ensure the absence 
of extra bands. Samples were quantified using KAPA 
qPCR quantification kit. Equimolar amounts of DNA were 
pooled for capture (8-12 samples per pool). 
Targeted capture and deep sequencing
A total of 202 genes that are clinically relevant in 
cancer were selected for capture (Supplemental Table 
6). The selection was based on mutational data in the 
Catalogue of Somatic Mutations in Cancer (COSMIC) 
and The Cancer Genome Atlas (TCGA) with a minimum 
of 3% frequency across disease sites or 5% disease 
specific frequency. We designed biotin labeled probes with 
Roche Nimblegen (Roche NimbleGen, Madison, WI) for 
capturing target regions (all exons in those 202 genes) 
and followed manufacture’s protocol for the capture step. 
Briefly, DNA was pooled (8-16 samples), dried out and 
after addition of the capture reagents and probes, samples 
were incubated at 47 °C on thermocycler with heated 
lid (57 °C) for 64-74 hours. The targeted regions were 
recovered using streptavidin beads and the streptavidin-
biotin-probe-target complex was washed and another 
round of PCR amplification was performed according 
to manufacturer’s protocol. The quality of each captured 
sample was analyzed on TapeStation using the DNA High 
Sensitivity kit and the enrichment was accessed by qPCR 
using specific primers designed by Roche Nimblegen. The 
cutoff for the enrichment was 50 fold minimum.
The captured libraries were sequenced on a HiSeq 
2000 (Illumina Inc., San Diego, CA) on a version 3 
TruSeq paired end flowcell according to manufacturer’s 
instructions at a cluster density between 700 - 1000 K 
clusters/mm2. Sequencing was performed on a HiSeq 2000 
for 2 × 100 paired end reads with a 7 nucleotide read for 
indexes using Cycle Sequencing v3 reagents (Illumina 
Inc., San Diego, CA). The resulting BCL files containing 
the sequence data were converted into “.fastq.gz” files and 
individual libraries within the samples were demultiplexed 
using CASAVA 1.8.2 with no mismatches. All regions 
were covered by >20 reads. Average depth of sequencing 
was 1135x across the T200 exons. Most of mutations 
(202/212) was supported by at least 500 reads, 10 was 
supported by at least 98 reads. Five of the ten mutations 
that did not reach 500x were from CDKN2A, due to a 
very high GC content at this site. Having a minimal 500x 
coverage ensures confident (<2% FDR) sensitive (>95% 
chance) detection of low frequency (1%) mutations.
SNV, CNV and LOH analysis
We aligned the T200 target-capture deep-
sequencing data to human reference assembly hg19 using 
the Burrows-Wheeler Alignment (BWA) tool [23] and 
removed duplicated reads using samtools [24]. We called 
single nucleotide variants (SNVs) and small indels using 
VarScan2 [25], which classified variants into 3 categories: 
somatic, germline, and loss of heterozygosity based on 
the difference of allele frequencies between the tumor 
and the matched normal tissues. To ensure specificity, 
variants with an allele frequency less than 5% were not 
reported. We called copy number alterations using a 
previously published algorithm [26], which reports gain 
or loss status of each exon. To understand the potential 
functional consequence of detected variants, we compared 
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them with dbSNP, COSMIC [27], and TCGA databases, 
and annotated them using VEP [28], Annovar [29], SIFT 
[30], Polyphen [31], Condel [32], Mutation Assessor [11] 
and CanDrA (Mao et al, unpublished). 
Microarray analysis
Processing of the Genome-Wide Human SNP 6.0 
arrays was performed using the Affymetrix GeneChip 
(Affymetrix p/n 901182) at the KUMC Microarray 
Facility. The labeled target was prepared using the 
SNP 6.0 Core Reagent Kit (Affymetrix p/n 901706) 
according to the Affymetrix Genome-Wide Human SNP 
Nsp/Sty 6.0 User Guide rev.7 (Affymetrix p/n 702504). 
The target preparation was initiated with the restriction 
digestion of separate 250 ng aliquots of each genomic 
DNA using Nsp I and Sty I restriction endonuclease. The 
individual restricted fragments underwent ligation with the 
appropriate Nsp or Sty adaptor containing a PCR Primer 
002 priming site. The ligated samples are diluted and 
PCR amplified using the PCR Primer 002 and Titanium 
DNA Amplification Kit (Clontech p/n 639240/639243). 
The Nsp amplification was performed in quadruplicate 
and the Sty amplification was performed in triplicate. The 
Nsp and Sty amplified fragments for each sample were 
pooled and purified using the Isopropanol Precipitation 
Method. Following quantification, the combined Nsp 
and Sty purified target samples were fragmented with 
DNase I and end labeled with biotin using Terminal 
Deoxynucleotidyl Transferase (TdT) and DNA labeling 
reagent. Biotin labeled-fragmented single stranded 
cDNA was hybridized to the Genome-Wide Human 
SNP 6.0 arrays according to manufacturer’s instructions. 
Hybridized, washed and R-phycoerythrin-streptavidin 
stained arrays were scanned using the GeneChip Scanner 
3000 7G with autoloader. Data collection was performed 
using the Command Console software (Affymetrix, Santa 
Clara, CA). Genotyping Console Software 4.2 (GTC) was 
used to analyze the copy number variation (CNV) and loss 
of heterozygosity (LOH) in five samples obtained from the 
patient with the larynx tumor and six samples obtained 
from the patient with an oral tongue tumor with regional 
GC correction.
Phylogenetic tree construction and tumor 
evolution 
Phylogenetic trees were generated to represent 
the intratumor heterogeneity and mutation evolutionary 
patterns and were estimated using the maximum 
likelihood approach [33], as implemented in PhyML [34]. 
Tumor samples were segregated by clusters of common 
and unique mutations in primary and metastatic sites. 
Synonymous and non-coding mutations were included in 
the analyses. An evolutionary model for each patient lists 
the genes with common and unique mutations in primary 
and metastatic tumors. Genes that acquired a common 
mutation during evolution in both primary and metastatic 
tumors are indicated next to normal (dark blue), and 
branches indicate unique mutations present in primary and 
metastatic sites (brown and orange, respectively). 
TCGA analysis
Somatic mutation data were downloaded from the 
public TCGA data repository website, cBioportal.org, from 
the Memorial Sloan Kettering Cancer Center. Data from 
172 oral cavity and 72 larynx SCC patients were included 
in the analysis. The number of patients with low (</=200) 
and high (>200) mutation counts were determined. 
Statistical analysis
Due to the small sample size, medians and ranges are 
reported for continuous patient and tumor characteristics. 
Frequencies and percentages are reported for categorical 
characteristics. Chi-square tests were used to investigate 
associations between mutation rates and primary tumor 
location (oral cavity versus larynx). Exact p-values are 
reported. The Frequency Procedure in SAS version 9.4 
was used. For TCGA datasets, the chi-square analysis was 
performed to determine if dichotomous mutation levels are 
associated with the site of tumor.
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